PARTI OVERVIEW We are a clinical-stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology. We seek to develop drug candidates in the precision medicine space, and our processes for selection and clinical development of drug candidates are based on scientific data into cancer-promoting factors, as well as our understanding of the clinical landscape and regulatory requirements. CORPORATE I...
Q2 FY2026 — expected 2026-09-12
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-02-11 | 2025-12-31 | 0001104659-26-013044 | EDGAR | 58K words |
| 2025-02-25 | 2024-12-31 | 0001558370-25-001496 | EDGAR | — |
| 2024-03-05 | 2023-12-31 | 0001558370-24-002497 | EDGAR | — |
| 2023-03-08 | 2022-12-31 | 0001558370-23-003181 | EDGAR | — |
| 2022-03-23 | 2021-12-31 | 0001104659-22-037110 | EDGAR | — |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-08-04 | 2026-06-30 | 0001104659-26-090109 | EDGAR | — |
| 2025-11-04 | 2025-09-30 | 0001104659-25-105939 | EDGAR | 35K words |
| 2025-08-05 | 2025-06-30 | 0001558370-25-010203 | EDGAR | — |
| 2025-05-06 | 2025-03-31 | 0001558370-25-006497 | EDGAR | — |
| 2024-11-05 | 2024-09-30 | 0001558370-24-014340 | EDGAR | — |
| 2024-08-06 | 2024-06-30 | 0001558370-24-010971 | EDGAR | — |
| 2024-05-07 | 2024-03-31 | 0001558370-24-007072 | EDGAR | — |
| 2023-11-08 | 2023-09-30 | 0001558370-23-018124 | EDGAR | — |
| 2023-08-09 | 2023-06-30 | 0001558370-23-014266 | EDGAR | — |
| 2023-05-10 | 2023-03-31 | 0001558370-23-009133 | EDGAR | — |
| 2022-11-08 | 2022-09-30 | 0001558370-22-016755 | EDGAR | — |
| 2022-08-10 | 2022-06-30 | 0001558370-22-013018 | EDGAR | — |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-08-04 | 0001104659-26-090094 | EDGAR | — |
| 2026-02-11 | 0001104659-26-013049 | EDGAR | 2K words |
| 2025-11-04 | 0001104659-25-105953 | EDGAR | — |
| 2025-09-25 | 0001104659-25-093144 | EDGAR | — |
| 2025-08-05 | 0001104659-25-073967 | EDGAR | — |
| 2025-06-13 | 0001104659-25-059435 | EDGAR | — |
| 2025-05-09 | 0001104659-25-046845 | EDGAR | — |
| 2025-05-06 | 0001104659-25-044838 | EDGAR | — |
| 2025-02-25 | 0001104659-25-016779 | EDGAR | — |
| 2025-02-06 | 0001104659-25-009813 | EDGAR | — |
66 total filings indexed. 39 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0001875558 |
| Ticker | NVCT |
| Exchange | Nasdaq |
| SIC | 2834: Pharmaceutical Preparations |
| Incorporated | DE |
| Website | https://www.nuvectis.com |
| Listed | 2022-02-04 |
This is a static snapshot. For live, structured JSON with cryptographic provenance chain:
MCP (recommended for AI): claude mcp add origin --transport http https://origin.rootz.global/mcp
Try it — paste this into your AI:
Works in ChatGPT, Claude, Gemini, or any AI. Free, structured, cryptographically signed — ~500 tokens vs 130,000 scraping an IR site.
claude mcp add origin --transport http https://origin.rootz.global/mcpGET https://origin.rootz.global/api/company/NVCT (~200 tokens, structured JSON with cryptographic provenance)